Allena Pharmaceuticals Inc

Allena Pharmaceuticals — Investor Presentation (January 2018)

30 slides from Allena Pharmaceuticals's investor presentation, Jan 8, 2018

  1. Slide 1: Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders

    Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders January 2018 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Allena Pharmaceuticals, Inc. These slides contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are

  3. Slide 3: 2017 Accomplishments Position Allena for Catalyst-Rich 2018

    2017 Accomplishments Position Allena for Catalyst-Rich 2018 …WITH IMPORTANT UPCOMING VALUE DRIVERS IN 2018 SIGNIFICANT MILESTONES ACHIEVED IN 2017 Completed robust Phase 2 clinical program, demonstrating substantial reduction of UOx excretion in patients with enteric hyperoxaluria Prepared to start

  4. Slide 4: Investment Highlights

    Investment Highlights Significant Unmet Need in Oxalate and Urate Disorders Late-Stage Development Candidate: ALLN-177 Pioneering Expertise in Oral Enzyme Therapeutics Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and ESRD

  5. Slide 5: Allena's Pipeline: First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders

    Product Indication Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Next Milestone Commercial Rights ALLN-177 Enteric hyperoxaluria Q1 ’18: Initiate Phase 3 program Worldwide Systemic oxalosis* Q1 ’18: Initiate Phase 2 program Worldwide Primary hyperoxaluria* (Orphan Designation) Q1 ’18: Initiate Phas

  6. Slide 6: Hyperoxaluria is characterized by markedly elevated urinary oxalate levels

    Hyperoxaluria is characterized by markedly elevated urinary oxalate levels Oxalate is a Metabolite that is Nephrotoxic at High Concentrations Source: Illustration adapted from Coe, Fred. “Control of Urine Oxalate Excretion.” Kidneystones.uchicago.edu. University of Chicago, http://kidneystones.uchic

  7. Slide 7: First-in-Class Therapeutic Strategy

    First-in-Class Therapeutic Strategy Expertise and Proprietary Technological Approach in Enzyme Therapeutics Enables First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders ALLN-177 Recombinant Protein Oral, non-absorbed, highly specific Optimized Highly Active Form of the Enzyme for GI T

  8. Slide 8: Enteric hyperoxaluria patients and high unmet need

    Gastric bypass surgery Crohn’s disease Short bowel syndrome Cystic fibrosis EH patients are diagnosed and treated by nephrologists and urologists often in Stone Clinics in academic and community settings High unmet need: more frequent and more complex stones; fail standard of care (i.e., hydration,

  9. Slide 9: ALLN-177 Initially Targets Enteric Hyperoxaluria Patients

    ALLN-177 Initially Targets Enteric Hyperoxaluria Patients with Underlying Malabsorptive GI Diseases and Kidney Stones 1 Truvan Health Analytics, part of the IBM Watson Health business longitudinal Claims Analysis, August 2017. Analysis tracked patients for whom an enteric disease diagnosis or proced

  10. Slide 10: Risk of Renal Complications Rises with Higher Urinary Oxalate Levels

    Risk of Renal Complications Rises with Higher Urinary Oxalate Levels: Reduction of UOx Improves Renal Outcomes Illustrative Diagram Sources: Robertson and Hughes, Scanning Microsc. 1993; Keddis Curr Opin Nephrol Hypertens. 2013; Robertson and Peacock, Nephron. 1980; Milliner, Kidney Int. 2006; Curha

  11. Slide 11: Kidney Week Highlights: Increasing Awareness of Oxalate Disorders

    Kidney Week Highlights: Increasing Awareness of Oxalate Disorders Silent Hyperoxaluria Contributes to CKD Progression in a Patient with Short Bowel4 Oxalate Nephropathy Leading to ESRD Following Roux-en-Y Gastric Bypass5 Oxalate Nephropathy: A Case of Acute Renal Failure from Chronic Pancreatitis6 T

  12. Slide 12: ALLN-177 for the Treatment of Hyperoxaluria

    ALLN-177 for the Treatment of Hyperoxaluria

  13. Slide 13: Clinical and Regulatory Progression of ALLN-177

    Clinical and Regulatory Progression of ALLN-177 Pre clinical Ph 1 Healthy Volunteers Ph 2 Open Label Ph 2 Randomized Controlled ✓ ✓ ✓ ✓ Porcine Rhubarb Model Presented at AUA 2016 Progressive Increase in Enzyme Activity Porcine Western Diet Model Presented at ASN 2016 n=30 A Double Blind, Placebo Co

  14. Slide 14: Robust Phase 2 Program Leads to Phase 3 Strategy for ALLN-177

    Goals Results Robust Phase 2 Program Leads to Phase 3 Strategy for ALLN-177 Phase 3 Phase 2 Program Phase 1 Open Label 396 Study: Demonstrated POC in kidney stone patients with hyperoxaluria (n=16; 5 EH) Adaptive 649 Study: Tested cross over design and multiple doses (n= 30; 8 EH) Parallel 713 Study

  15. Slide 15: Study 713: Study Design and Baseline Characteristics

    ALLN-177 n=32 Placebo n=35 Enteric ALLN-177 n=11 Enteric Placebo n=7 Baseline urinary oxalate (mg/24h) 71.81 (41.35) 66.81 (38.22) 104.39 (56.04) 101.54 (70.42) Study 713: Study Design and Baseline Characteristics Sources: Taylor et al. Oxalate Intake and the Risk for Nephrolithiasis. J Am Soc Nephr

  16. Slide 16: Study 713: Substantial Treatment Effect in Enteric Hyperoxaluria Population

    Study 713: Substantial Treatment Effect in Pre-specified Enteric Hyperoxaluria Population from Baseline to TWA Across 4 Weeks vs Placebo UOx: Urinary oxalate excretion (mg/24 h) LS means, LS differences (treatment – placebo), 90% confidence intervals and one-sided p-values are obtained from the MMRM

  17. Slide 17: Greater ALLN-177 Treatment Response in Enteric Population

    Substantially Greater ALLN-177 Treatment Response in Enteric Population Provides Design Space for Phase 3 Program Beyond the primary endpoint analysis, all P-values are descriptive. Enteric ALLN-177 Enteric Placebo Change in TWA Urinary Oxalate (mg/24h) Baseline Urinary Oxalate (mg/24h) Change in TW

  18. Slide 18: Enteric Patients Demonstrated Differential Treatment Effect in Study 396

    Enteric Patients Also Demonstrated Differential Treatment Effect in 4 Day Open Label Study 396 Mean UOx Change from Baseline n=16 n=5 Baseline (mg/24h) Change in UOx from Baseline (mg/24h) Change in UOx from Baseline (mg/24h) Change in UOx Excretion vs Baseline UOx Excretion

  19. Slide 19: ALLN-177 Generally Well-Tolerated in Clinical Trials to Date

    ALLN-177 Generally Well-Tolerated in Clinical Trials to Date 11,500 u/meal, 3,000 u/meal, and 7,500 u/meal. 2TEAE = Treatment emergent adverse events are defined as AEs with onset at the time of or following the first dose of treatment with study drug through 7 days after their last dose of study me

  20. Slide 20: Completed Robust Phase 2 Clinical Program

    Completed Robust Phase 2 Clinical Program Identified Proposed Phase 3 Patient Population Substantially reduced UOx in patients with EH, a high-risk population Well tolerated, with no drug-related serious or severe adverse events Specific to oxalate, with minimal to no changes in non-oxalate urine pa

  21. Slide 21: ALLN-177: Proposed Pivotal Phase 3 Program in Enteric Hyperoxaluria

    1H 2017 2H 2017 1H 2018 2H 2018 1H 2019 2H 2019 1H 2020 2H 2020 1H 2021 ALLN-177: Proposed Pivotal Phase 3 Program in Enteric Hyperoxaluria Proposed Phase 3 Program – in Discussions with the FDA: 301: Primary endpoint – TWA UOx weeks 1-4 302: Primary endpoint – TWA UOx weeks 1-4, 24 weeks plus follo

  22. Slide 22: Key Points of General FDA Alignment for the Registrational Program

    Key Points of General FDA Alignment for the Registrational Program: Change in TWA UOx levels potentially approvable endpoint Dosing up to 5x day with meals and snacks Phase 2 program in secondary hyperoxaluria supports Phase 3 program in enteric hyperoxaluria Enteric hyperoxaluria is a rare disease

  23. Slide 23: Additional ALLN-177 Regulatory Highlights

    Additional ALLN-177 Regulatory Highlights Public-private partnership by the American Society of Nephrology in collaboration with stakeholders in the renal community including the FDA The Kidney Health Initiative recently endorsed a project to bring together patients, clinicians, industry and the FDA

  24. Slide 24: Recent Metabolic and Rare Disease Products Registered on Biochemical Endpoints

    Recent Metabolic and Rare Disease Products Have Been Registered on the Basis of Biochemical Endpoints Source: www.accessdata.fda.gov/scripts/cder/daf/index.cfm Uremic Toxin Product Biochemical Endpoint for FDA Approval Measurement Phosphate Ferric citrate Changes in serum phosphorous from baseline (

  25. Slide 25: ALLN-177 Additional Indications

    ALLN-177 Additional Indications

  26. Slide 26: ALLN-177 Potential to Reduce Plasma Oxalate in Severe Hyperoxaluria

    ALLN-177 has the Potential to Reduce Plasma Oxalate in Severe Enteric and Primary Hyperoxaluria Patients with Hyperoxalemia *Pigs not colonized with oxalobacter formigenes. Sources: Company data, Health Advances Allena Market Strategy February 2017. Zh. ALLN-177 Therapy Degraded Oxalate in the GI Tr

  27. Slide 27: Phase 2 Basket Study of ALLN-177 in Hyperoxaluria and Hyperoxalemia

    Screening and Baseline 28 d Follow up 4 Weeks Phase 2 'Basket' Study: ALLN-177 Treatment of Adult and Pediatric Patients with Enteric or Primary Hyperoxaluria and Hyperoxalemia Primary Hyperoxaluria (PH) Enteric Hyperoxaluria (EH) Urinary Oxalate (UOx) Plasma Oxalate (POx) Regulatory: ALLN-177 has b

  28. Slide 28: ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD

    ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD The Gout Market is Incompletely Served by Existing Therapies ~375,000 gout patients with moderate to severe CKD who have uncontrolled gout on urate lowering therapy (ULT) Gout patients with renal impairment are not well m

  29. Slide 29: Forecasted Clinical and Regulatory Milestones

    Forecasted Clinical and Regulatory Milestones 2018 1Q18 Initiate Study 301 in Enteric Hyperoxaluria 1Q18 Initiate Study 206 in Primary or Enteric Hyperoxaluria and Hyperoxalemia 2H18 Initiate Study 302 in Enteric Hyperoxaluria 2H18 Interim Data in Study 206 2019 1H19 File IND for ALLN-346 in Hyperur

  30. Slide 30: Investment Highlights

    Investment Highlights Significant Unmet Need in Oxalate and Urate Disorders Late-Stage Development Candidate: ALLN-177 Pioneering Expertise in Oral Enzyme Therapeutics Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and ESRD

Allena Pharmaceuticals — Investor Presentation (January 2018) on 6ix